Clopidogrel (II): Conferring over the Kung Pao

Clopidogrel, proton pump inhibitors, calcium channel blockers, CYP2C19, CYP3A4

Abstract

This case further discusses the aggregation of risk factors for significant drug–drug interactions involving clopidogrel, proton pump inhibitors, and calcium channel blockers.

Keywords

Pharmacokinetic Inhibitor Inhibition Clopidogrel Prodrug Platelet aggregation Antiplatelet effect Thrombosis Coronary artery stent Proton pump inhibitor Calcium channel blockers CYP3A4 CYP P450 Cytochrome 3A4 2C19 Verapamil Diltiazem CYP2C19 CYP2C19*2 More metabolizer Omeprazole Pantoprazole 

References

  1. 1.
    Drepper MD, Spahr L, Frossard JL, et al. Clopidogrel and proton pump inhibitors – where do we stand in 2012? World J Gastroenterol. 2012;18(18):2161–71.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2010;96(3):186–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Harmsze AM, van Werkum JW, Souverein PC, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost. 2011;9(10):1892–901.PubMedCrossRefGoogle Scholar
  4. 4.
    Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52(19):1557–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Bhurke SM, Martin BC, Li C, et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012;32(9):809–18.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Fontes-Carvalho R, Albuquerque A, Araújo C, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol. 2011;23(5):396–404.PubMedCrossRefGoogle Scholar
  7. 7.
    Schmidt M, Johansen MB, Robertson DJ, et al. Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. Eur J Clin Invest. 2012;42(3):266–74. Epub 2011 Aug 11.PubMedCrossRefGoogle Scholar
  8. 8.
    Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013;167(3):965–74.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Anesthesia Services DepartmentPhiladelphia Veterans Affairs Medical CenterPhiladelphiaUSA
  2. 2.Department of PsychiatryUniversity of Maryland Medical SystemBaltimoreUSA
  3. 3.Department of PsychiatryVA Maryland Health Care SystemBaltimoreUSA

Personalised recommendations